These patients have successfully gone through a series of screening procedures and they quantitatively differed in their cellular protein expression and activation profiles, tumor growth kinetics, and the proportion of different cancer cell clones within the tumors to together reflect the interindividual variability in MET-aberrant NSCLC patients (see Methods for more details regarding virtual patient generation). This evidence concerns the gene MET and cancer.